智通财经网·2025-08-23 03:56Core Findings - The study published in the Journal of the American Medical Association Oncology indicates that GLP-1 receptor agonists, such as Eli Lilly's Mounjaro and Novo Nordisk's Ozempic, can reduce cancer risk [1] - The research analyzed electronic health records of over 80,000 obese patients without prior cancer history, revealing a statistically significant decrease in overall cancer risk among users of GLP-1 medications compared to non-users [1] Study Details - The study utilized data from the OneFlorida+ health research network, covering 43,315 non-users and 43,317 users of GLP-1 medications from 2014 to 2024 [1] - Among patients using GLP-1 medications, the incidence rate of 14 types of cancers (including 13 obesity-related cancers) was 13.6 cases per 1,000 individuals per year, compared to 16.4 cases per 1,000 for non-users [1] Additional Insights - The study also noted a slight but not statistically significant increase in the risk of kidney cancer associated with GLP-1 medications [1] - Researchers emphasize the need for long-term follow-up studies to assess the clinical significance and underlying reasons for the findings due to the retrospective nature of the study [2]